Wednesday, July 8, 2026
🇺🇸 FDA

pharma · No medical condition. · Breast cancer

George Institute for

The George Institute

George Institute for clinical programs — 406 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

George Institute for projects

406 ClinicalTrials.gov programs sponsored by George Institute for.

George Institute for has 406 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

406 programs

Clinical programs

Page 3 of 9

  1. 2017/2558

    The George Institute

    Resectable mucosal melanomas

    phase 2 small molecule active

    1 trial

  2. 2020-004696-41

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  3. 2020/3093 NIRADO

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  4. 2021/3330 HOLMBRAVE

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  5. 2022/3418 INDIGO

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  6. 2023/3610 NEOSARC

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  7. 2023/3668

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  8. 2024/3967

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  9. 2025-521877-14-00

    The George Institute

    Traumatic spinal cord injury

    phase 2 other active

    1 trial

  10. 2G-MSC-GVHD

    The George Institute

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  11. 68Ga-FAPI-46

    The George Institute

    Non-metastatic Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. 68Ga-FAPI-46

    The George Institute

    Triple-negative breast cancer (TNBC) patients at high risk of relapse

    phase 2 small molecule active

    1 trial

  13. ABP-2019

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  14. ADJUBIL

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  15. ADMSC-fib safety and efficacy in patients with chronico wounds

    The George Institute

    chronic wounds

    phase 2 other active

    1 trial

  16. ALDESLEUKIN for Germ Cell Tumors refractory to salvage chemotherapy

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  17. ARI-HER2

    The George Institute

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  18. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  19. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. ASPIRE

    The George Institute

    Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.

    phase 2 small molecule active

    1 trial

  21. ATEZOLIZUMAB

    The George Institute

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

  22. AdaptNK –Cell Therapy for High-risk Myeloid Disease

    The George Institute

    Relapsed and/or refractory AML or MDS

    phase 2 other active

    1 trial

  23. AloCelyvir

    The George Institute

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  24. Amimox filmdragerade tabletter for Need of Oral bone augmentation

    The George Institute

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  25. BAY 73-4506, AVELUMAB

    The George Institute

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  26. BCN04-DASA

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

  27. BDTX-4933-101

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  28. BOOST cells

    The George Institute

    Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.

    phase 2 small molecule active

    1 trial

  29. BOTULINUM TOXIN , -

    The George Institute

    Myogenous temporomandibular disorders (TMDM)

    phase 2 small molecule active

    1 trial

  30. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    The George Institute

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  31. Busulfan /ml concentrate for High-risk myeloïd malignancies

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  32. Byetta 10 micrograms solution for injection in pre-filled pen

    The George Institute

    Hypopituarism

    phase 2 small molecule active

    1 trial

  33. C12-48

    The George Institute

    Recessive dystrophic epidermolysis bullosa (RDEB)

    phase 2 small molecule active

    1 trial

  34. CART19-BE-02

    The George Institute

    Acute lymphoid leukemia

    phase 2 small molecule active

    1 trial

  35. CARTBCMA-HCB-01

    The George Institute

    Multiple Myeloma

    phase 2 other active

    1 trial

  36. CAT-01

    The George Institute

    Cervical carcinoma

    phase 2 other active

    1 trial

  37. CBD-ESPRIT

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  38. CIALIS 5 mg film-coated tablets

    The George Institute

    sexual/ erectile function in women and men after treatment for rectal cancer

    phase 2 small molecule active

    1 trial

  39. CIRCULATE-SPAIN-01

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  40. CL1-65487-003

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  41. CL1-95012-001

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  42. CL1-95029-002

    The George Institute

    MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer

    phase 2 small molecule active

    1 trial

  43. CL1-95035-001

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  44. CLEAN-DUCT

    The George Institute

    Extrahepatic cholangiocarcinoma (eCCA)

    phase 2 small molecule active

    1 trial

  45. CSET 2020/3187

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  46. CSET 2022-3571

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  47. CSET 2025/4053

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  48. CSET N° 2017/2523

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

Frequently asked questions

How many clinical projects does George Institute for have?

406 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.